While Human Genome Sciences Inc. (HGSI) is open to a permanent relationship, the biotech is making it pretty clear that it wants a suitor that truly values what it has to offer.
The FDA got an earful Monday at a hearing on how to best modernize clinical trials and good clinical practice (GCP), but most of the ideas have been on the table for many years, one stakeholder pointed out.
WASHINGTON – Hopes for a mean, lean PDUFA bill that would cruise speedily through Congress are being dashed as lawmakers, and industry, continue to add their pet extras.
WASHINGTON – The reauthorization of PDUFA could lead to a change in mission for the FDA that would require the agency to couple economic growth and job creation with its public health duties.
Five Prime Therapeutics Inc. added another notch to its growing list of biologics-development relationships with big pharma players, signing on with GlaxoSmithKline plc for their second partnership.
When is a sales rep not a sales rep? That's the question the Supreme Court faced Monday as it heard arguments in a case that could change the 70-year-old paradigm of pharma sales reps.
When patent protection expired in November for Pfizer Inc.'s Lipitor (atorvastatin), many mourned its passing as the end of the golden age of mega blockbusters.
WASHINGTON – The SEC has its work cut out for it in implementing the new Jumpstart Our Business Startups (JOBS) Act. But before it rolls up its sleeves, it's turning to the public for guidance.
On its way to the public trough, ArQule Inc. decided to go for a bigger portion, opting to increase its underwritten offering to 7.15 million shares priced at $7.30 per share.
